Prof. Dr. Zipeto Donato
University of Verona, Italia
Response to vaccination in naïve versus previously SARS-CoV-2 infected subjects
Autori: Luca Dalle Carbonare1, Maria Teresa Valenti1, Zeno Bisoffi2,3, Chiara Piubelli2, Massimo Pizzato4, Silvia Accordini4, Sara Mariotto5, Sergio Ferrari5, Arianna Minoia1, Jessica Bertacco1, Veronica Li Vigni1, Gianluigi Dorelli1, Ernesto Crisafulli1, Daniela Alberti5, Laura Masin5, Natalia Tiberti2, Silvia Stefania Longoni2, Lucia Lopalco6, Alberto Beretta7, DONATO ZIPETO5*
1Department of Medicine, University of Verona
2Department of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar (Verona)
3Department of Diagnostics and Public Health, University of Verona
4Department of Cellular, Computational and Integrative Biology, University of Trento, Povo (Trento)
5Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona
6Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milan
7Covi2 Technologies Srl, Novara
We profiled antibody responses in a cohort of recipients of the BTN162b2 mRNA vaccine who were either immunologically naïve (n=50) or had been previously infected with SARSCoV-2 (n=51). Of the previously infected, 25 and 26 were infected during the first and second pandemic waves in Italy, respectively; the majority of those from the first wave had corresponding waning antibody titres with low to undetectable levels of anti-S antibodies and low anti-N antibodies. We observed in recipients who had been previously infected that spike-specific IgG and pseudovirus neutralization titres were rapidly recalled by a single vaccine dose to higher levels than those in naïve recipients after the second vaccine dose, irrespective of waning antibody responses. In all recipients, a single vaccine dose was sufficient to induce a potent IgA response that was not associated with serum neutralization titres.
A. Personal Statement:
My current specific areas of expertise include molecular biology and genome editing (CRISPR/Cas9 technique) and
molecular virology. Current research interests are the analysis of the interactions between viral and cellular proteins, the
study of MHC-I variants related to HIV infection progression to AIDS, the study of the relationship between viral infections
and neurodegenerative diseases, and the study of the immunity against SARS-CoV-2.
B. Positions and Honors
Associate Professor in Molecular Biology, University of Verona (2014-current)
Assistant Professor in Molecular Biology, University of Verona (2002-2014)
Teaching duties: molecular biology, Basics of Molecular Virology and Gene Therapy, Pharmacogenomics, Human
Retroviruses, zoonosis and emerging viruses.
Main Grants and Awards:
Brain Research Foundation Verona, Project “Neurotropism of SARS-CoV-2: virological, cellular, molecular and
pathogenetic aspects (2020).
Gilead Fellowship Program Grant, project “HIV-associated neurocognitive disorders: a clinical, virological and
immunological approach to early definition of biomarkers” (2019)
EUROPRISE Innovation Award, “Analysis of the interaction between HLA-C and HIV-1 Env”, European Commission, 6th
6th FP, “European Vaccines and Microbicides Enterprise”. European Commission EUROPRISE Project (2007-2011)
2014-2020: Expert evaluator, European Commission, REA, H2020-HSCA-IF, LIF Panel
2016-2017: Post-project evaluator, Baltinfect Project, Riga Stradina University, Riga (LV)
2014-2018: GHIT Fund Reviewer, Japanese R&D for Global Health
2014: Expert evaluator, European Commission, H2020-PCH-2014-two-stage (01, 03, 17, 18, 22)
2010-2014: Expert evaluator, European Commission, REA, FP7-PEOPLE, Life Panel
2009: Evaluator NHLS Research Trust Grant
C. Editorial Activity
Guest Editor for the Journal of Immunology Research, Special Issue on “Inflammation in Cancer: Part of the problem or Part
of the Solution?”, 2018 and 2020.